Science


Unmet Medical Need: Vein Graft Failure

It has been shown (PREVENT III and PREVENT IV) that Vein Graft failure (VGF) occurs in 39% and 46% of patients 12-18 months post procedure (peripheral bypass and CABG, respectively), with the VA Cooperative Study demonstrating a 39% graft failure rate at 10 years (CABG).

VGF often leads to significant morbidity, which can include recurrent symptoms, myocardial infarction, limb loss and/or death. Health economic consequences, including need for expensive re-do procedures, and limb loss present a significant cost burden for health care systems.

The leading cause of VGF, intimal hyperplasia, is at least partly due to vein graft injury caused by the surgical harvest/graft preparation procedure prior to implantation in the recipient site.

Graft preparation typically uses a combination of vessel dilation, the use of toxic skin markers and acidic preservation solutions, resulting in endothelial and smooth muscle damage, functional vessel death and ultimately intimal hyperplasia.

VasoPrep Surgical’s technology portfolio aims to address harvest- and preparation-associated injury and includes:

  • Proprietary, non-toxic surgical marker and ink technology to preserve endothelial function
  • Pressure release technology to limit vessel distention and stretch injury
  • Convenience items that aim to standardize and facilitate vein preparation procedures

This technology has been proven in scientific preclinical (or non-clinical) studies at Vanderbilt University using human saphenous vein, porcine saphenous vein and rabbit vein graft models.

 

For more information, see PUBLICATIONS page.